TIAA CREF Investment Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
Sell
-650,350
Closed -$228 3162
2016
Q3
$228 Hold
650,350
﹤0.01% 3036
2016
Q2
$303K Buy
650,350
+111,742
+21% +$52.1K ﹤0.01% 3030
2016
Q1
$733K Hold
538,608
﹤0.01% 2631
2015
Q4
$792K Hold
538,608
﹤0.01% 2715
2015
Q3
$851K Buy
538,608
+13,334
+3% +$21.1K ﹤0.01% 2663
2015
Q2
$893K Buy
525,274
+83,972
+19% +$143K ﹤0.01% 2746
2015
Q1
$613K Buy
441,302
+21,473
+5% +$29.8K ﹤0.01% 2857
2014
Q4
$634K Sell
419,829
-27,303
-6% -$41.2K ﹤0.01% 2883
2014
Q3
$921K Sell
447,132
-21,451
-5% -$44.2K ﹤0.01% 2676
2014
Q2
$1.43M Sell
468,583
-376,221
-45% -$1.15M ﹤0.01% 2499
2014
Q1
$2.11M Buy
844,804
+231,456
+38% +$579K ﹤0.01% 2207
2013
Q4
$3.04M Buy
613,348
+312,335
+104% +$1.55M ﹤0.01% 1983
2013
Q3
$683K Sell
301,013
-22,191
-7% -$50.4K ﹤0.01% 2840
2013
Q2
$718K Buy
+323,204
New +$718K ﹤0.01% 2788

TIAA CREF Investment Management's RXII Position: Q4 2016 in Review

TIAA CREF Investment Management sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 650,350 shares — an estimated $228 sold.

TIAA CREF Investment Management first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $3.04M in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

  • TIAA CREF Investment Management reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
  • TIAA CREF Investment Management sold 650,350 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $228.
  • TIAA CREF Investment Management first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
  • TIAA CREF Investment Management's GALENA BIOPHARMA INC COM position peaked at $3.04M in Q4 2013.
  • 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on TIAA CREF Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.